Clinical Trials
33
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
- Conditions
- SCASpinocerebellar Ataxias
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Registration Number
- NCT06034886
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
- Conditions
- SMANeuromuscular DiseasesSpinal Muscular Atrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT05337553
- Locations
- 🇺🇸
Phoenix Children's, Phoenix, Arizona, United States
🇺🇸UCSD & Rady Children's, La Jolla, California, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
- Conditions
- Multiple System Atrophy (MSA)
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Registration Number
- NCT05086094
- Locations
- 🇺🇸
PPD, Morrisville, North Carolina, United States
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT04708834
- Locations
- 🇺🇸
Metropolitan Neuro Behavioral Institute, Chandler, Arizona, United States
🇺🇸Alea Research, Phoenix, Arizona, United States
🇺🇸NoeisisPharma, LLC, Phoenix, Arizona, United States
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT04693351
- Locations
- 🇺🇸
Alea Research, Phoenix, Arizona, United States
🇺🇸ProScience Research Group, Culver City, California, United States
🇺🇸Kaizen Brain Center, La Jolla, California, United States
- Prev
- 1
- 2
- 3
- Next
News
Biohaven's Obesity Program Gains Analyst Confidence Despite SMA Trial Setback
• Baird maintains an Outperform rating for Biohaven, encouraged by positive body composition changes observed in a Phase 3 SMA trial, signaling potential in the upcoming Phase 2 obesity trial. • Biohaven's management expresses strong optimism for their degrader platform, anticipating key results soon, which contributes to the positive outlook despite the recent Phase 3 SMA trial failure. • Despite a setback in the Phase 3 trial of taldefgrobep for spinal muscular atrophy (SMA), analysts remain confident in Biohaven's broader R&D portfolio, particularly its obesity program.